Systemic Sclerosis – A Diagnostic Challenge or a Clinically Controllable Disease?
DOI:
https://doi.org/10.12775/QS.2025.42.60484Keywords
systemic sclerosis, scleroderma, autoimmunity, vasculopathy, fibrosis, EULAR recommendationsAbstract
Systemic sclerosis is a complex and heterogeneous autoimmune condition in which skin and internal organ involvement progresses through interrelated processes of vasculopathy, immune activation, and fibrosis. Although considered an uncommon disease, its impact is disproportionate due to delayed diagnosis and potential for multiorgan complications. This review aims to synthesize current knowledge on the underlying mechanisms, clinical spectrum, and management strategies of systemic sclerosis, with particular attention to validated classification criteria and therapeutic recommendations. The paper emphasizes the role of early clinical suspicion, specific serologic and capillaroscopic findings, and the significance of evolving immunomodulatory and antifibrotic therapies. An individualized and multidisciplinary approach remains essential in improving patient outcomes and quality of life.
References
Allanore Y., Simms R., Distler O. et al. (2015) Systemic sclerosis. Nature Reviews Disease Primers 1:15002. https://doi.org/10.1038/nrdp.2015.2
Avouac J., Fransen J., Walker U.A. et al. (2011) Preliminary criteria for the very early diagnosis of systemic sclerosis (VEDOSS): results of a Delphi Consensus Study from the EULAR Scleroderma Trials and Research group. Annals of the Rheumatic Diseases 70(3):476–481. https://doi.org/10.1136/ard.2010.136929
Bruni C., De Luca G., Lazzaroni M.-G. et al. (2020) Screening for pulmonary arterial hypertension in systemic sclerosis: A systematic literature review. European Journal of Internal Medicine 78:17–25. https://doi.org/10.1016/j.ejim.2020.05.042
Bruni C., Ross L. (2021) Cardiac involvement in systemic sclerosis: getting to the heart of the matter. Best Practice & Research Clinical Rheumatology 35(3):101668. https://doi.org/10.1016/j.berh.2021.101668
Chung L., Liu J., Parsons L. et al. (2014) Survival and predictors of mortality in systemic sclerosis–associated pulmonary arterial hypertension. Arthritis Care & Research 66(3):489–495. https://doi.org/10.1002/acr.22121
Cole A., Ong V.H., Denton C.P. (2023) Renal disease and systemic sclerosis: an update on scleroderma renal crisis. Clinical Reviews in Allergy & Immunology 64(3):378–391. https://doi.org/10.1007/s12016-022-08945-x
Cutolo M., Sulli A., Smith V. (2013) How to perform and interpret capillaroscopy in systemic sclerosis. Best Practice & Research Clinical Rheumatology 27(2):237–248. https://doi.org/10.1016/j.berh.2013.03.001
Dein E., Kuo P.L., Hong Y.S. et al. (2019) Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Seminars in Arthritis and Rheumatism 49(3):405–410. https://doi.org/10.1016/j.semarthrit.2019.05.005
Del Galdo F., Lescoat A., Matucci-Cerinic M. et al. (2025) EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Annals of the Rheumatic Diseases 84(1):29–40. https://doi.org/10.1136/ard-2024-226430
Distler O., Highland K.B., Gahlemann M. et al. (2019) Nintedanib for systemic sclerosis–associated interstitial lung disease. New England Journal of Medicine 380(26):2518–2528. https://doi.org/10.1056/NEJMoa1903076
Downes T.J., Cheruvu M.S., Karunaratne T.B. et al. (2018). Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction. Journal of Clinical Gastroenterology 52(6):477–489 https://doi.org/10.1097/mcg.0000000000001047
Elhai M., Meune C., Boubaya M. et al. (2017) Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases 76(11):1897–1905. https://doi.org/10.1136/annrheumdis-2017-211448
Galie N., Barbera J.A., Frost A.E. et al. (2015) Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine 373(9):834–844. https://doi.org/10.1056/NEJMoa1413687
Garros A., Marjoux S., Khouatra C., et al. (2017) Prevalence of fecal incontinence in a cohort of systemic sclerosis patients within a regional referral network. United European Gastroenterology Journal 5(7):1046–1050. https://doi.org/10.1177/2050640616688129
Ghrénassia E., Avouac J., Khanna D. et al. (2014) Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case–control study. Journal of Rheumatology 41(1):99–105. https://doi.org/10.3899/jrheum.130386
Hamaguchi, Y. & Takehara, K. (2018). Anti-nuclear autoantibodies in systemic sclerosis: News and perspectives. Journal of Scleroderma and Related Disorders 3(3):201–213. https://doi.org/10.1177/2397198318783930
Herrick A.L. (2011) Contemporary management of Raynaud’s phenomenon and digital ischemic complications. Current Opinion in Rheumatology 23(6):555–561. https://doi.org/10.1097/bor.0b013e32834aa40b
Hoffmann-Vold A.M., Aaløkken T.M., Lund M.B. et al. (2015) Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis. Arthritis & Rheumatology 67(8): 2205–2212. https://doi.org/10.1002/art.39166
Hsu V.M., Varga J., Schlesinger N. (2019) Calcinosis in scleroderma made crystal clear. Current Opinion in Rheumatology 31(6):589–594. https://doi.org/10.1097/bor.0000000000000658
Hudson M., Baron M., Tatibouet S. et al. (2014) Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis: results from the International Scleroderma Renal Crisis Survey. Seminars in Arthritis and Rheumatism 43(5):666–72 https://doi.org/10.1016/j.semarthrit.2013.09.008
Khanna D., Lin C.J.F., Furst D.E. et al. (2020) Tocilizumab in systemic sclerosis: a randomized, double-blind, placebo-controlled, phase 3 trial (focuSSced). Lancet Respiratory Medicine 8(10):963–974. https://doi.org/10.1016/S2213-2600(20)30110-X
Knobler R., Berlin G., Calzavara-Pinton P. et al. (2014) Guidelines on the use of extracorporeal photopheresis. Journal of the European Academy of Dermatology and Venereology 28(Suppl 1):1–37 https://doi.org/10.1111/jdv.12311
Koenig M., Joyal F., Fritzler M.J. et al. (2008) Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients. Arthritis & Rheumatism 58(12):3902–3912. https://doi.org/10.1002/art.24038
Korn J.H., Mayes M., Matucci-Cerinic M. et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis & Rheumatism 50(12):3985–3993. https://doi.org/10.1002/art.20676
Kowal-Bielecka O., Landewé R., Avouac J. et al. (2009) EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group. Annals of the Rheumatic Diseases 68(5):620–628 https://doi.org/10.1136/ard.2008.096677
Kreuter A., Breuckmann F., Uhle A. et al. (2004) Low-dose UVA1 phototherapy in systemic sclerosis: effects on acrosclerosis. Journal of the American Academy of Dermatology 50(5):740–747. https://doi.org/10.1016/j.jaad.2003.08.026
Kucharz E.J., Kopeć-Mędrek M. (2017) Systemic sclerosis sine scleroderma. Advances in Clinical and Experimental Medicine 26(5):875–880. https://doi.org/10.17219/acem/64334
Lefebvre F., Giannini M., Ellezam B. et al. (2021) Histopathological features of systemic sclerosis-associated myopathy: a scoping review. Autoimmunity Reviews 20(7):102851 https://doi.org/10.1016/j.autrev.2021.102851
McMahan Z.H. (2019) Gastrointestinal involvement in systemic sclerosis: an update. Current Opinion in Rheumatology 31(6):561–568. https://doi.org/10.1097/BOR.0000000000000645
Miele C.H., Schwab K.E., Saggar R., et al. Lung transplant outcomes in systemic sclerosis with significant esophageal dysfunction: A comprehensive single-center experience. Annals of the American Thoracic Society 13(6): 793–802. https://doi.org/10.1513/annalsats.201512-806oc
Mouthon L., Bussone G., Berezné A. et al. (2014) Scleroderma renal crisis. Journal of Rheumatology 41(6):1040–1048. https://doi.org/10.3899/jrheum.131210
Nguyen, A.D., McMahan, Z.H., Volkmann, E.R. (2022). Micronutrient Deficiencies in Systemic Sclerosis: A Scoping Review. Open Access Rheumatology 14:309–327. https://doi.org/10.2147/OARRR.S354736
Nihtyanova S.I., Sari A., Harvey J. et al. (2020) Using autoantibodies and cutaneous subset to develop outcome-based disease classification in systemic sclerosis. Arthritis & Rheumatology 72(3):465–476. https://doi.org/10.1002/art.41153
Pauling J.D., Hughes M., Pope J.E. (2019) Raynaud’s phenomenon – an update on diagnosis, classification and management. Clinical Rheumatology 38(12):3317–3330. https://doi.org/10.1007/s10067-019-04745-5
Penn H., Howie A.J., Kingdon E.J. et al. (2007) Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 100(8):485–494. https://doi.org/10.1093/qjmed/hcm052
Solomon J.J., Olson A.L., Fischer A. et al. (2013) Scleroderma lung disease. European Respiratory Review 22(127):6–19. https://doi.org/10.1183/09059180.00005512
Steen V.D., Medsger T.A. (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis & Rheumatism 43(11):2437–2444. https://doi.org/10.1002/1529-0131(200011)43:11%3C2437::aid-anr10%3E3.0.co;2-u
Steen V.D., Oddis C.V., Conte C.G. et al. (1997) Incidence of systemic sclerosis in Allegheny County, Pennsylvania: a 20-year study of hospital-diagnosed cases, 1963–1982. Arthritis & Rheumatism 40(3):441–445. https://doi.org/10.1002/art.1780400309
Stochmal A., Czuwara J., Trojanowska M. et al. (2020) Antinuclear antibodies in systemic sclerosis: an update. Clinical Reviews in Allergy & Immunology 58(1):40–51. https://doi.org/10.1007/s12016-018-8718-8
Sullivan K.M., Goldmuntz E.A., Keyes-Elstein L. et al. (2018) Myeloablative autologous stem-cell transplantation for severe scleroderma. New England Journal of Medicine 378(1):35–47 https://doi.org/10.1056/nejmoa1703327
Tang R., Yu J., Shi Y. et al. (2020) Safety and efficacy of rituximab in systemic sclerosis: a systematic review and meta-analysis. International Immunopharmacology 83:106389. https://doi.org/10.1016/j.intimp.2020.106389
Tashkin D.P., Elashoff R., Clements P.J. et al. (2006) Cyclophosphamide versus placebo in scleroderma lung disease. New England Journal of Medicine 354(25):2655–2666. https://doi.org/10.1056/nejmoa055120
Tashkin D.P., Roth M.D., Clements P.J. et al. (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respiratory Medicine 4 (9):708–719 https://doi.org/10.1016/s2213-2600(16)30152-7
van den Hoogen F., Khanna D., Fransen J. et al. (2013) 2013 classification criteria for systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases 72(11):1747–1755. https://doi.org/10.1136/annrheumdis-2013-204424
van Laar J.M., Farge D., Sont J.K. et al. (2014) Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311(24):2490–2498. https://doi.org/10.1001/jama.2014.6368
Varga J., Abraham D. (2007) Systemic sclerosis: a prototypic multisystem fibrotic disorder. Journal of Clinical Investigation 117(3):557–567. https://doi.org/10.1172/JCI31139
Volkmann E.R., Andréasson K., Smith V. (2023) Systemic sclerosis. The Lancet 401(10373):304–318. https://doi.org/10.1016/s0140-6736(22)01692-0
Young A., Moles V.M., Jaafar S. et al. (2021) Performance of the DETECT algorithm for pulmonary hypertension screening in a systemic sclerosis cohort. Arthritis & Rheumatology 73(9):1731–1737 https://doi.org/10.1002/art.41732
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Olga Kądziołka, Karolina Skonieczna, Magdalena Badziąg, Paulina Szulc, Laura Kurczoba, Martyna Kłossowska, Olimpia Wiciun, Kacper Ordon
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 144
Number of citations: 0
